• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Mark Lebwohl, MD, Appointed to Vial Dermatology CRO Scientific Advisory Board

Article

Vial Dermatology CRO announced that Mark Lebwohl, MD, a Dermatology Times® Board member, as an addition to its dermatology CRO, which was launched earlier this year.

The Vial Dermatology contract research organization (CRO)has added Mark Lebwohl, MD, to the Vial scientific advisory board. Lebwohl will help both the Vial CRO team and sponsors working to advance the Dermatology research field. The Vial CRO was launched earlier this year and taglined as “The CRO Built for Sponsors,” the new organization is powered by the Vial Clinical Network which is comprised of more than 35 dermatology clinics throughout the United States.

The Vial scientific advisory board’s dermatology KOLs will service sponsors in clinical strategy, regulatory strategy, trial design, and indication selection, according to the press release.

Betsey Zbyszynski leads the Vial CRO team as the head of clinical operations. The team includes Jason Shuris as head of sales; Janet DuBois, MD, a dermatologist and principal researcher at DermResearch in Austin, Texas, as medical director; Justin Withers as head of dermatology; and Mamta Hunt as head of quality. The Vial CRO executive team have a combined 100+ years of dermatology clinical trial experience.

“The development of a technology-centric CRO that can drive much-needed progress in dermatology research is exciting, and I’m delighted to join their scientific advisory board,” Lebwohl said.

Lebwohl has served as president of the New York Dermatological Society, the Manhattan Dermatologic Society, and the New York State Society of Dermatology, and as chairman of the Dermatology Section of the New York Academy of Medicine. He is a past chairman of the Psoriasis Task Force of the American Academy of Dermatology (AAD), and has directed the AAD's annual Psoriasis Symposium, Diagnostic Update Symposium and Therapeutics Symposium as well as the academy’s annual meeting and summer meeting.

Lebwohl is chairman emeritus of the Medical Board of the National Psoriasis Foundation. He is the founding editor of Psoriasis Forum and the Journal of Psoriasis and Psoriatic Arthritis. He has been on the editorial board of the Journal of the American Academy of Dermatology and the Journal of Skin Cancer. He is editor of the dermatology section of Scientific American Medicine and co-Editor-in-Chief of Skin, the Journal of Cutaneous Medicine. He has authored or co-authored over 600 publications including articles, chapters, and abstracts. He is also a member of Dermatology Times® editorial board.

Reference:

Vial announces Mark Lebwohl to scientific advisory board. Cision PR Newswire. Press release. Published March 1, 2022. Accessed March 1, 2022. https://www.prnewswire.com/news-releases/vial-announces-dr-mark-lebwohl-to-scientific-advisory-board-301492550.html

Related Videos
© 2024 MJH Life Sciences

All rights reserved.